{"url_path":"/sec/hura/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1498382/0001193125-26-227245-index.html","accession_number":"0001193125-26-227245","cik":"0001498382","ticker":"HURA","issuer_name":"TuHURA Biosciences, Inc./NV","edgar_url":"https://www.sec.gov/Archives/edgar/data/1498382/0001193125-26-227245-index.html","primary_entity_key":"0001498382","primary_entity_name":"TuHURA Biosciences, Inc./NV"},"word_count":409,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n \n\n[Articles of Incorporation of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.), as amended (incorporated by reference to Exhibit 3.1 to TuHURA’s Registration Statement on Form S-1 filed with the SEC on August 12, 2025)](https://www.sec.gov/Archives/edgar/data/1498382/000119312525179009/d898723dex31.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) (incorporated by reference to Exhibit 3.1 to TuHURA’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022)](https://www.sec.gov/Archives/edgar/data/1498382/000095017022023988/ktra-ex3_1.htm)\n\n10.1*\n\n \n\n \n\n[First Amendment to Loan Agreement, dated as of May 15, 2026, between TuHURA Biosciences, Inc. and Parkview Holdings One LLC.](hura-ex10_1.htm)\n\n10.2*\n\n \n\n \n\n[Consulting Agreement, dated March 18, 2026, between TuHURA Biosciences, Inc. and Tendler Biotech Consulting, LLC.](hura-ex10_2.htm)\n\n31.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](hura-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](hura-ex31_2.htm)\n\n32.1**\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](hura-ex32_1.htm)\n\n32.2**\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](hura-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n* Filed herewith.\n\n** This certification is being furnished solely to accompany this Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n \n\n \n\n27\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nTUHURA BIOSCIENCES, INC.\n\nDated: May 15, 2026\n\nBy:\n\n/s/ James A. Bianco, M.D.\n\nJames A. Bianco\n\nPresident and Chief Executive Officer\n\n \n\n (Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nDated: May 15, 2026\n\nBy:\n\n/s/ Dan Dearborn\n\n \n\n \n\n \n\nDan Dearborn\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial Officer)\n\n \n\n \n\n28"}